Links to the American Heart Association 2022 late-breaking studies

Dave Fornell | November 11, 2022 | Cardiovascular Business | American Heart Association (AHA)

Image from the American Heart Association (AHA) annual scientific sessions where a large amount of late-breaking cardiology science is presented. #AHA #AHA22 #AHA2022

The American Heart Association (AHA) has announced 35 late-breaking studies and 42 featured science sessions being presented at the 2022 annual meeting in Chicago, Nov. 5-7.

Late-Breaking Science: The Main Event: Changing Clinical Practice

LBS.01, Saturday, Nov. 5, 9:30-10:30 a.m., Main Event I

• Comparative Effectiveness of Torsemide Versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial

• Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients With Hypertension (DCP)

• A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease (PROMINENT)

Late-Breaking Science: Breakthrough Strategies in the HF Journey

LBS.02, Saturday, Nov. 5, 3-4 p.m., Main Event I

• First-in-Human in vivo CRISPR/Cas9 Editing of the Ttr Gene by Ntla-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy

• A Patient-Risk Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial

• Early Results of the Patient-Reported Outcome Measurement in Heart Failure Clinic (PRO-HF) Trial

• IRONMAN: A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction

Late-Breaking Science: High Impact Trials in Intervention and Surgery

LBS.03, Sunday, Nov. 6, 8-9 a.m., Main Event I

• Radial Artery Patency and Clinical Outcomes (RAPCO) Randomized Trials—The 15-Year Clinical Outcomes Comparing Radial Artery With Right Internal Thoracic Artery or With Saphenous Vein Grafting (RAPCO)

• Steroids to Reduce Systemic Inflammation After Infant Heart Surgery: The STRESS Trial

• The Impact of Chinese Herbal Medicine, Tongxinluo in Patients With Acute Myocardial Infarction—Results From the CTS-AMI Trial

• Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Primary Results From the Multicenter, Randomized ECMO-CS Trial

Late-Breaking Science: Mindful Disruption of Chronic HTN Management

LBS.04, Sunday, Nov. 6, 3:30-4:30 p.m., Main Event I

• Effectiveness of a Village Doctor-Led Multifaceted Implementation Strategy on Cardiovascular Disease Among Patients With Hypertension: A Cluster Randomized Trial (CRHCP)

• Reducing Inequities in Care of Hypertension: Lifestyle Improvement for Everyone: Blood Pressure and Patient-Reported Outcomes (The Rich Life Project)

• The Effect of Adapted Mindfulness Training in Participants With Elevated Office Blood Pressure: The Mindfulness-Based Blood Pressure Reduction (MB-BP) Randomized Clinical Trial (The MB-BP Study) - accepted, not confirmed

• Efficacy and Safety of a Quadruple Ultra-Low-Dose Treatment for Hypertension (QUARTET USA) Randomized Controlled Trial

Late-Breaking Science: Changing How We Prevent Cardiovascular and Renal Disease

LBS.05, Sunday, Nov. 6, 5-6 p.m., Main Event I

• Randomized Trial for Evaluating Secondary Prevention Efficacy of Combination Therapy—Statin and Eicosapentaenoic Acid (RESPECT-EPA)

• Reduction of Lipoprotein(a) With Small Interfering RNA: The Results of the OCEAN(a)-DOSE Trial

• Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial

• Effect of Low-Dose Statin Compared With Placebo and Six Dietary Supplements on Lipid and Inflammatory Biomarkers: The SPORT Randomized Clinical Trial

Late-Breaking Science: Drugs and Strategies in ACS and Revascularization

LBS.06, Sunday, Nov. 6, 5-6 p.m., Main Event II

• Bivalirudin With a Post-PCI High-Dose Infusion Versus Heparin Monotherapy During Primary PCI in STEMI: The Randomized Bright-4 Trial (BRIGHT-4)

• Efficacy and Safety of Indobufen Versus Aspirin After Coronary Drug-Eluting Stent Implantation: A Randomized, Open-Label, Non-Inferiority Trial (OPTION)

• Comparison of a Precision Care Strategy With Usual Testing to Guide Management of Stable Patients With Suspected Coronary Artery Disease: The PRECISE Randomized Trial

• VIDEO: PRECISE trial shows cardiac CT with FFR-CT significantly improves patient outcomes

• ISCHEMIA-EXTENDed Follow-Up Interim Report

Late-Breaking Science: Preventing Limb Loss Through Vascular Interventions and Venous Therapies

LBS.07, Monday, Nov. 7, 8-9 a.m., Main Event I

• Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Clinical Results (BEST-CLI)

• Best Endovascular Versus Best Surgical Therapy for Patients With Chronic Limb Threatening Ischemia (BEST-CLI) Trial: Quality of Life Analyses (BEST-CLI)

• Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With COVID-19: Primary Results of the PREVENT-HD Randomized Clinical Trial (PREVENT-HD)

• A Multicenter Clustered Randomized Trial of a Universal Electronic Health Record-Based Venous Thromboembolism Risk Assessment Model as Integrated Clinical Decision Support for Prevention of Thromboembolism in Hospitalized Medically Ill Patients (IMPROVE Trial)

Late-Breaking Science: Treating Atrial and Supraventricular Arrhythmias

LBS.08, Monday, Nov. 7, 11 a.m.-Noon, Main Event I

• The Impact of Cryoablation as a “First-Line” Rhythm Therapy on Atrial Fibrillation Progression: The PROGRESSIVE-AF Trial

• VIDEO: Cryoablation can be used as frontline therapy before drugs: PROGRESSIVE AF trial

• Self-Administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis From the RAPID Study

• Efficacy and Safety of Botulinum Toxin Type A for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery Patients: Results From the Phase 2 NOVA Study

• Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision-Making Pathway (ENHANCE-AF)

Late-Breaking Science: Resistant HTN: A Pressure Cooker

LBS.09, Monday, Nov. 7, 3-4 p.m., Main Event I

• Top-Line Results of The First-in-Class Aminopeptidase-A Inhibitor Firibastat in Treatment-Resistant Hypertension (FRESH) Study

• Sustained Blood Pressure Lowering Effect With the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results From a Randomized, Controlled Study Including a Withdrawal Phase (PRECISION)

• Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients With Treatment-Resistant Hypertension (BrigHTN)

• Effect of Radiofrequency Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 6-Month Primary Results From the SPYRAL HTN-ON Med Expansion Randomized Trial

Featured Science Sessions:

In-Depth and Fresh Look in Heart Failure Trials

FS.01, Sunday, Nov. 6, 8-9 a.m.

• The Effect of Percutaneous Revascularization on Arrhythmic Risk in Ischemic Left Ventricular Dysfunction (REVIVED-BCIS2)

• Natriuretic Response With Acetazolamide in Acute Heart Failure With Volume Overload: Analysis From the ADVOR Trial

• Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Pre-Specified Analysis From the ADVOR Trial

• Empagliflozin and Cardiac Remodeling in People Without Diabetes: Primary Results of EMPA-HEART 2 CardioLink-7 Randomized Placebo-Controlled Trial

• First and Repeat Episodes of Worsening Heart Failure in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction: An Analysis of DELIVER

New Insights — Cardiac Surgery

FS.02, Sunday, Nov. 6, 9:30 -10:30 a.m.

• Myosin Inhibition in Patients With Obstructive HCM Referred for Septal Reduction Therapy: 32-Week Active Blinded Crossover Results From VALOR-HCM Trial

• Electrocardiographic Changes After Cardiac Surgery and 30-Day Mortality (VISION Cardiac Surgery)

• Interim Results of a Phase 2 Study With RBT-1 Evaluating Post-operative Course in Patients Undergoing Elective CABG/Valve Surgery on Cardiopulmonary Bypass (The START Study)

• Results From the Clinical Implementation of Partial Oral Treatment of Patients With Infectious Endocarditis; A Nationwide Study. Time for Poetry?

Featured Science in Heart Rhythm Medicine

FS.03, Sunday, Nov. 6, 5-6 p.m.

• Feasibility and Safety of Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients With Atrial Fibrillation - DASH-AF Study

• Subcutaneous Implantable Cardioverter-Defibrillator System Post Approval Study: Primary Results (S-ICD PAS)

• Apixaban or Vitamin K Antagonists for Stroke Prevention in Patients With Atrial Fibrillation on Hemodialysis: Results of the Randomized AXADIA-AFNET 8 Trial

• Association of Genetic Risk and Outcomes in Patients With Early Rhythm Control Therapy in Atrial Fibrillation: Results From the EAST-AFNET4 Study

Emerging Heart Failure Science

FS.04, Monday, Nov. 7, 8-9 a.m.

• Safety and Efficacy of Non-Ischemic Hypothermic Machine Perfusion (NIHP) in Human Heart Transplantation With an Ischemic Time of 6-8 Hours

• A Randomized, Multicenter, Placebo-Controlled Trial of the Beta3 Adrenergic Agonist, Mirabegron on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease, the BETA3LVH Trial

• The Prelieve Trial: Final 1-Year Outcomes of the Prospective Atrial Flow Regulator Study in Heart Failure Patients and Responder Analysis (Prelieve)

• Exercise for the Prevention of Anthracycline-Induced Functional Disability and Cardiac Dysfunction: The Breast Cancer Exercise Intervention (BREXIT) Study

• Dissemination of a Decision Support Tool for Left Ventricular Assist Device: How a Majority of United States Programs Implemented I-DECIDE-LVAD into Standard Patient Evaluations

Evolving Science in COVID-19

FS.05, Monday, Nov. 7, 8-9 a.m.

• Anti-c5a Vilobelimab Reduces All-Cause Mortality in Critically Ill COVID-19 Patients and in Those With Comorbid Hypertension: A Phase 3 Randomized Double-Blind, Placebo-Controlled Study (PANAMO)

• A Randomized Trial of Lipid Metabolism Modulation With Fenofibrate for Acute Coronavirus Disease 2019 (FERMIN)

• Impact of Coronavirus Disease-2019 on Participants in Deliver (DELIVER)

• Rare Coding Variants in Cardiomyopathy-Associated Genes Predispose to Severe COVID-19 and Cardiac Injury (COVID-CARDOGEN)

• Prevalence of Myocarditis Among Patients Hospitalized With Laboratory-Confirmed SARS-CoV-2 Infection ion 14 U.S. States, March 2020-May 2022 (COVID-NET)

Optimal Management Post-PCI/ACS

FS.06, Monday, Nov. 7, 9:30-10:30 a.m.

• Long-Term Outcomes of an Invasive versus Conservative Strategy in Stabilised Patients Aged 80 Years or Older With Non-ST-Elevation Acute Coronary Syndrome, After Eighty Study: A Randomised Controlled Trial (After Eighty Study)

• Long-Term Follow-Up of Aspirin vs. Clopidogrel Monotherapy in the Chronic Maintenance Period After Percutaneous Coronary Intervention: The Host-Exam Extended Study

• Impact of Ticagrelor With or Without Aspirin on Total and Recurrent Bleeding and Ischemic Events After PCI: Results From the TWILIGHT Recurrent Events Sub-Study

• Effect of Semaglutide on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes: Final Results of the STOP study

A Second Look at Practice-Changing Heart Failure Trials

FS.07, Monday, Nov. 7, 11 a.m.-Noon

• The Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Results From the DELIVER Trial

• Baseline Characteristics, Outcomes, and Treatment Response to Dapagliflozin in Patients Treated With an MRA or ARNI in DELIVER

• Sex Differences in Characteristics, Outcomes and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure (DAPA-HF, DELIVER)

• Differences in Clinical Characteristics, Outcomes, and Treatment Response to Dapagliflozin Across the Range of Ejection Fraction in Black and White Patients With Heart Failure: A Pooled Analysis of DAPA-HF and DELIVER

• Comparison of Clinical Outcomes and Efficacy of Empagliflozin in Black vs White Patients With Heart Failure: A Pooled Analysis From the EMPEROR Program (EMPEROR-Pooled)

• Long-Term Survival After Cardiac Resynchronization in Ambulatory Heart Failure (RAFT)

Digital Innovations to Improve CVD Prevention

FS.08, Monday, Nov. 7, 11 a.m.-Noon

• Randomized, Controlled Trial of Digital Nutritional Cognitive Behavioral Therapy in Patients With Type 2 Diabetes Mellitus: Primary Outcomes of the BT-001 Pivotal Trial at 180 Days (BT001 PIVOTAL)

• A Randomized Controlled Trial of a Remotely Delivered Mobile Health Intervention to Augment Cardiac Rehabilitation: The Virtual AppLication-Supported ENvironment To INcrease Exercise VALENTINE Study

• Smartphone-Based Cardiovascular Risk Reduction in Breast Cancer Patients [Smart-Breast]: A Randomized Controlled Trial (SMART-BREAST)

• A PRagmatic Trial Of Messaging to Providers About Treatment of HyperLIPIDemia (PROMPT-LIPID)

• Incidental Coronary Artery Calcium: Opportunistic Screening of Prior Non-Gated Chest CTs to Improve Statin Rates (NOTIFY-1)

The Present and Future of Lipid Lowering

FS.09, Monday, Nov. 7, 3-4 p.m.

• ARO-ANG3, an Investigational RNAi Therapeutic, Decreases Serum Angiopoietin-Like Protein 3, Triglycerides, and Cholesterol in Patients With Mixed Dyslipidemia (ARCHES-2)

• ARO-APOC3, an Investigational RNAi Therapeutic, Decreases Serum Apolipoprotein C3, Triglyceride, and Non-HDL-C Concentrations While Increasing HDL-C in Patients With Severe Hypertriglyceridemia (SHASTA-2)

• Long-Term Efficacy of Very Low LDL-Cholesterol Levels With the PCSK9 Inhibitor Evolocumab: Analysis of the FOURIER and FOURIER-OLE Studies (FOURIER-OLE)

• Efficacy and Safety of Twice-Yearly Subcutaneous Inclisiran in Patients With High Cardiovascular Risk and Elevated Low-Density Lipoprotein Cholesterol up to 4 Years-The Orion-3 Trial

• Individual Participant Data Meta-Analysis of New-Onset and Worsening Diabetes Mellitus in Large-Scale Randomized Double-Blind Trials of Statin Therapy

Find more information on the AHA late-breaking science and other featured sessions using the AHA Online Program Planner.

Former surgeon general says cardiologists need to address hypertension and remaining COVID cases

FDA Commissioner Robert Califf calls on cardiology to address health inequities and combat misinformation

VIDEO: Key takeaways from AHA 2022

TCT 2022 late-breaking clinical presentations announced

Links to all the late-breaking structural heart studies at TVT 2022

Links to all the SCAI 2022 late-breaking clinical research

Links to the late-breaking studies at Heart Rhythm 2022

Links to the ACC.22 late-breaking clinical trials

Dave Fornell

Dave Fornell has covered healthcare for more than 17 years, with a focus in cardiology and radiology. Fornell is a 5-time winner of a Jesse H. Neal Award, the most prestigious editorial honors in the field of specialized journalism. The wins included best technical content, best use of social media and best COVID-19 coverage. Fornell was also a three-time Neal finalist for best range of work by a single author. He produces more than 100 editorial videos each year, most of them interviews with key opinion leaders in medicine. He also writes technical articles, covers key trends, conducts video hospital site visits, and is very involved with social media. E-mail: dfornell@innovatehealthcare.com

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.